Ignite Creation Date:
2025-12-24 @ 11:37 PM
Ignite Modification Date:
2025-12-25 @ 9:27 PM
Study NCT ID:
NCT04201756
Status:
COMPLETED
Last Update Posted:
2022-12-23
First Post:
2019-12-04
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma
Sponsor:
Shanghai Pulmonary Hospital, Shanghai, China
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-07-26
Start Date Type:
ACTUAL
Primary Completion Date:
2022-02-28
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-08-30
Completion Date Type:
ACTUAL
First Submit Date:
2019-12-04
First Submit QC Date:
None
Study First Post Date:
2019-12-17
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-12-21
Last Update Post Date:
2022-12-23
Last Update Post Date Type:
ACTUAL